• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Paxlovid Not Helpful for Reducing Most Post-COVID-19 Conditions

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Oct. 31, 2023 -- Outpatient treatment of COVID-19 with nirmatrelvir-ritonavir (Paxlovid) reduces the risk for combined thromboembolic events, but does not affect the risk for other post-COVID-19 conditions (PCCs), according to a study published online Oct. 31 in the Annals of Internal Medicine.

George N. Ioannou, B.M.B.Ch., from the University of Washington in Seattle, and colleagues examined the effectiveness of outpatient treatment with nirmatrelvir-ritonavir for preventing PCCs in a retrospective target trial emulation study involving nonhospitalized veterans. Participants were at risk for severe COVID-19 and tested positive for severe acute respiratory syndrome coronavirus 2 during January through July 2022. The cumulative incidence of 31 matched potential PCCs at 31 to 180 days after treatment or a matched index date was examined.

The researchers observed no differences in the incidence of most PCCs examined individually or grouped by organ system between participants treated with nirmatrelvir-ritonavir (9,539 participants) and matched untreated comparators, apart from a lower combined risk for venous thromboembolism and pulmonary embolism (subhazard ratio, 0.65; cumulative incidence difference, −0.29 percent).

"Out of 31 potential PCCs that we examined, only combined thromboembolic events (venous thromboembolism and pulmonary embolism) seemed to be reduced by nirmatrelvir-ritonavir," the authors write. "Our results suggest that considerations about PCCs may not be an important factor in COVID-19 treatment decisions."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.